ARWR — Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Loss: $132.7 million, or $0.93 per share, compared to a net income of $370.4 million, or $2.75 per share, in Q2 2025. The previous year's income was bolstered by a significant transaction with Sarepta.
• Revenue: $74 million, primarily from collaboration agreements with Sarepta ($42 million) and Novartis ($20 million). The company did not report significant REDEMPLO sales yet, estimating around $1 million for the quarter.
• Expenses: Total operating expenses were approximately $215 million, up from $162 million in the prior year, driven by increased R&D and SG&A costs.
• Cash Position: Cash and investments totaled nearly $1.8 billion, supported by a recent $1 billion fundraising effort.

2. Strategic Updates and Business Highlights

• Product Launch: REDEMPLO, approved in November 2025 for treating familial chylomicronemia syndrome (FCS), continues to see strong prescription growth, with over 400 prescriptions written since launch and a weekly increase of about 30 new prescriptions.
• Pricing Strategy: The U.S. wholesale acquisition cost for REDEMPLO was reduced to $45,000 per year to enhance market access and simplify payer negotiations.
• Regulatory Approvals: Positive regulatory actions for REDEMPLO were secured in Canada, Australia, China, and a favorable opinion from the European Medicines Agency.
• Pipeline Expansion: The company has over 20 clinical programs, with several key readouts expected in the second half of 2026, including Phase III studies for plozasiran and early data for ARO-DIMER-PA and ARO-MAPT.

3. Forward Guidance and Outlook

• Upcoming Milestones: Key data releases are anticipated in Q3 2026 for plozasiran's Phase III studies, ARO-DIMER-PA, and ARO-MAPT, which could significantly impact the company's valuation and market position.
• SHTG Expansion: Plans to file a supplemental NDA for plozasiran to expand its indication to severe hypertriglyceridemia (SHTG) are underway, with potential regulatory approval expected in 2027.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: The pricing strategy for REDEMPLO may face challenges as Ionis announced a lower price for its APOC3 inhibitor, raising questions about maintaining a premium price point.
• Market Access: While payer interactions have been positive, the need for genetic confirmation for FCS patients might still pose barriers to access if not addressed adequately.
• Financial Performance: The significant net loss and lower revenue compared to the previous year highlight financial pressures, particularly as the company invests heavily in R&D and commercialization efforts.

5. Notable Q&A Insights

• Payer Interactions: Management indicated that recent pricing adjustments were not due to payer pushback but rather a strategic move to enhance access as they prepare for SHTG expansion.
• Clinical Expectations: There is cautious optimism around the upcoming readouts for plozasiran, with management confident in the strength of their clinical data.
• ARO-MAPT Strategy: The company is prepared to pursue multiple tauopathies regardless of the outcomes from competing studies, indicating a flexible approach to their pipeline strategy.
• Business Development: The recent licensing agreement with Madrigal Pharmaceuticals for ARO-PNPLA3 was framed as a strategic decision to partner with a focused NASH company, allowing Arrowhead to allocate resources to other promising programs.

Overall, Arrowhead Pharmaceuticals is positioned for growth with a strong pipeline and ongoing commercial efforts, despite facing competitive pressures and financial challenges.